£5.5M
The seed round was co-led by Montage Ventures and AIX Ventures to fund asset expansion and clinical trials.
"We're thrilled to have the support of this leading investor syndicate in our mission to rescue promising yet struggling drugs with our technology. Traditional safety assessments reveal when something is wrong, but our platform goes a step further by identifying the exact molecular and biological issues to provide actionable insights to re-engineer and revive therapies. With this funding, we can expand our efforts to salvage distressed assets and accelerate the delivery of life-saving therapies to patients."
